NCT01413165: Phase 4, Open Label, Multicentre, 2 Year Safety Study of Lisdexamfetamine Dimesylate in Children/Adolescents With ADHD |
|
|
| Not yet recruiting | 4 | 12 | Europe | Lisdexamfetamine dimesylate, SPD 489 | Maastricht University Medical Center, Shire Development LLC | Attention Deficit Disorder With Hyperactivity | 08/13 | 12/13 | | |
| Recruiting | 3 | 201 | US | Personalized Cognitive-behavioral therapy, Behavioral Interventions for Anxiety in Children with Autism, Standard Practice Cognitive-behavioral therapy, Coping Cat | Temple University, University of California, Los Angeles, University of South Florida, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Autism Spectrum Disorders, Autism, Asperger's Syndrome, Pervasive Developmental Disability - Not Otherwise Specified, Obsessive-compulsive Disorder, Social Phobia, Generalized Anxiety Disorder, Specific Phobia, Separation Anxiety Disorder | 01/17 | 01/17 | | |
NCT01233856: Omega-3 Fatty Acids as an Adjunctive Therapy for Treatment in Attention-Deficit Hyperactivity Disorder (ADHD) |
|
|
| Recruiting | N/A | 30 | US | Lovaza, Placebo (corn oil). | Maimonides Medical Center, GlaxoSmithKline | Attention-Deficit/Hyperactivity Disorder | 06/12 | 06/12 | | |